Sernova Biotherapeutics Inc
SVA.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.66% | 53.71% | 48.35% | 32.15% | 18.07% |
| Total Depreciation and Amortization | -37.86% | -9.43% | -4.02% | 7.59% | 20.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 67.31% | -60.19% | -57.97% | -55.65% | -50.95% |
| Change in Net Operating Assets | -84.52% | -76.13% | -61.38% | -15.85% | 119.93% |
| Cash from Operations | 44.40% | 45.94% | 42.98% | 34.29% | 38.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -72.34% | -31.74% | -68.51% |
| Cash from Investing | -99.78% | -99.96% | -72.32% | -31.59% | -68.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 33.23% | 13.14% | 0.88% | 2.09% | 1.57% |
| Issuance of Common Stock | -94.90% | 32,893.67% | 32,893.67% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 489.87% | -144.54% | -133.86% | -77.80% | -98.83% |
| Cash from Financing | -2.39% | 3,434.82% | 4,611.07% | 3,203.43% | 897.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -102.35% | 62.93% | 86.03% | 67.93% | -153.25% |